Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

AttackMS: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation

NCT05418010 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT05418010
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05418010 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
AttackMS: Natalizumab for the Treatment of People With Inflammatory Demyelination Suggestive of Multiple Sclerosis, or Definite Multiple Sclerosis, at First Presentation
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Recruiting
Start date
December 1, 2022
Completion date
October 31, 2027
Enrollment
40 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

clinically isolated syndrome of demyelination, multiple sclerosis